Skip to main
BLFS
BLFS logo

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc has exhibited significant revenue growth, with Cell Processing revenue increasing to $23.0 million, representing a 28% year-over-year growth, while evo and Thaw revenue reached $2.5 million, marking a 44% increase year-over-year. Additionally, management has enhanced its 2025 revenue guidance to a range of $100-103 million, indicative of expected ongoing growth with Cell Processing projected at $91.0-93.0 million and evo and Thaw at $9.0-10.0 million. Furthermore, the company anticipates a reduction in net loss and continued expansion of adjusted EBITDA margins, highlighting a strong growth trajectory and financial improvement.

Bears say

BioLife Solutions Inc's outlook is negatively affected by several fundamental risks, particularly the potential for lower-than-projected growth in products and services, which could hinder revenue generation. The company's net loss for the period was significantly greater than forecasts, totaling $15.8 million, attributed largely to substantial R&D expenses linked to the PanTHERA transaction. Furthermore, the revised revenue guidance for FY2025 reflects a decrease of approximately $8 million in expected revenue, indicating a challenging growth trajectory, particularly for its primary revenue driver, the Cell Processing platform.

BioLife Solutions (BLFS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.